Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis

Mao, Li; Li, Zhenlu; Wang, Zihe; Yue, Chao; Hu, Weiming; Lu, Honglin

doi:10.1007/s10238-021-00785-x

Cited by 26 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high SII, which signifies high neutrophil or platelet counts and/or low lymphocyte counts, is correlated with poor prognosis in PCa patients and may follow the mechanism mentioned above. Apparently, our results showed that poor survival outcomes of PCa patients were associated with high SII regardless of tumor type, ethnicity and cutoff value, consistent with several previous studies focused on SII and other solid tumors [ 50 , 68 , 69 ]. Our results indicated that the SII also played a crucial role in the prediction of prognosis in PCa, which proved the tight connection between the progression of PCa and the status of the immune system.…”

Section: Discussionsupporting

confidence: 91%

“…In recent years, SII, an index based on blood tests, has shown great potential as a complementary item for the prediction of survival in patients with malignancies. The impact of SII on the prognosis of solid tumors, including breast cancer [ 43 ], pancreatic cancer [ 44 ], lung cancer [ 45 ], and cervical cancer [ 46 ], as well as solid tumors of the urinary system, such as bladder cancer [ 47 ], has been reported in many studies. Several studies of SII have been summarized in such systematic reviews and meta-analyses, which provided penetrating insight into the association between SII and solid tumors, such as colorectal cancer [ 48 ], uterine cervical cancer [ 49 ], breast cancer [ 24 ], and pancreatic cancer [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

“…The impact of SII on the prognosis of solid tumors, including breast cancer [ 43 ], pancreatic cancer [ 44 ], lung cancer [ 45 ], and cervical cancer [ 46 ], as well as solid tumors of the urinary system, such as bladder cancer [ 47 ], has been reported in many studies. Several studies of SII have been summarized in such systematic reviews and meta-analyses, which provided penetrating insight into the association between SII and solid tumors, such as colorectal cancer [ 48 ], uterine cervical cancer [ 49 ], breast cancer [ 24 ], and pancreatic cancer [ 50 ]. The majority of these studies showed that a high SII is associated with poor prognosis in patients with such cancers.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Meng

Yang

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Background The systemic immune-inflammation index (SII) is a novel biomarker to predict the prognosis of some malignant tumors based on neutrophil, platelet, and lymphocyte counts. Evidence is scarce about the prognostic value of SII for prostate cancer patients. This systematic review and meta-analysis was conducted to explore the prognostic value of the SII in prostate cancer. Methods The PubMed, Embase, Web of Science, and Cochrane Library (CENTRAL) databases were searched to determine eligible studies from inception to August 15, 2022. Hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to pool the results. Statistical analyses were conducted by using Stata 17.0 software. Results A total of 12 studies with 8083 patients were included. The quantitative synthesis showed that a high SII was related to poor overall survival (OS) (HR = 1.44, 95% CI 1.23–1.69, p < 0.001). Furthermore, a subgroup analysis showed that a high SII was associated with poor OS in the groups of any ethnicity, tumor type, and cutoff value. An increased SII was also associated with inferior progression-free survival (PFS) (HR = 1.80, 95% CI 1.27–2.56, p = 0.001). In the subgroup analysis, a high SII value was related to poor PFS in Asian patients (HR = 4.03, 95% CI 1.07–15.17, p = 0.04) and a cutoff value > 580 (HR = 1.19, 95% CI 1.04–1.36, p = 0.01). Conclusion Based on the current evidence, a high pretreatment SII may be associated with poor OS and PFS. The SII may serve as an important prognostic indicator in patients with prostate cancer. More rigorously designed studies are needed to explore the SII and the prognosis of prostate cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Meng

Yang

et al. 2023

J Transl Med

View full text Add to dashboard Cite

show abstract

“…SII is an indirect inflammatory index that combines peripheral blood platelet count, neutrophil count and lymphocyte count, which can reflect the immune and inflammatory status of patients more comprehensively. It was used to predict mortality in patients with malignancy and acute disease [7], and Esenboğa et al [19] found that elevated SII was independently associated with no recurrent flow in patients with STEMI undergoing PCI. In a recent study, lnSII > 5.91 × 10 9 /L was one of the independent predictors of the development of CI-AKI after PCI in STEMI patients [20].…”

Section: Discussionmentioning

confidence: 99%

“…Systemic immune-inflammation index (SII) as well as small and dense low-density lipoprotein (sd-LDL) are both clinically accessible and inexpensive quantitative biochemical markers. SII is a novel inflammatory index initially used to predict poor clinical outcomes in various cancers and inflammatory diseases [7], and in recent years studies have found that SII is associated with mortality and prognosis in patients with cardiovascular disease [8]. Sd-LDL is more likely to cause atherosclerosis than LDL, and is an independent risk factor for cardiovascular disease [9].…”

Section: Introductionmentioning

confidence: 99%

Predictive value of SII and sd-LDL for contrast-induced acute kidney injury in STEMI patients undergoing percutaneous coronary intervention

Shen

Wang

et al. 2022

Exploration of Medicine

View full text Add to dashboard Cite

Aim: To investigate the relationship between the incidence of contrast-induced acute kidney injury (CI-AKI) and the level of small dense low-density lipoprotein (sd-LDL) and systemic immune-inflammation index (SII) in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing emergency percutaneous coronary intervention (PCI), and to further compare the predictive values of SII, sd-LDL and their combination for CI-AKI. Methods: A total of 674 patients were assigned to a training and a validation cohort according to their chronological sequence. The baseline characteristics of the 450 patients in the training cohort were considered as candidate univariate predictors of CI-AKI. Multivariate logistic regression was then used to identify predictors of CI-AKI and develop a prediction model. The predictive values of SII, sd-LDL and their combination for CI-AKI were also evaluated. Results: Multivariate logistic regression analysis showed that age, left ventricular ejection fraction (LVEF), sd-LDL, uric acid, estimated glomerular filtration rate (eGFR) and SII were predictors of CI-AKI. The area under the curve (AUC) of the prediction model based on the above factors was 0.846 [95% confidence interval (CI) 0.808–0.884], and the Hosmer-Lemeshow test (P = 0.587, χ2 = 6.543) proved the goodness of fit of the model. The AUC combining SII with sd-LDL to predict CI-AKI was 0.785 (95% CI 0.735–0.836), with a sensitivity of 72.8% and a specificity of 79.8%, and was statistically significant when compared with SII and sd-LDL, respectively. The predictive efficiency of combining SII with sd-LDL and SII were evaluated by improved net reclassification improvement (NRI, 0.325, P < 0.001) and integrated discrimination improvement (IDI, 0.07, P < 0.001). Conclusions: Both SII and sd-LDL can be used as predictors of CI-AKI in STEMI patients undergoing emergency PCI, and their combination can provide more useful value for early assessment of CI-AKI.

show abstract

Association Between Systemic Immune‐Inflammation Index and Psoriasis, Psoriasis Comorbidities, and All‐Cause Mortality: A Study Based on NHANES

Zhao,

Bai,

2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectiveThe relationship between systemic immune‐inflammation index (SII) and psoriasis and its prognosis is not yet clear. In this study, the correlation between SII and psoriasis, psoriasis comorbidities, and all‐cause mortality was investigated based on the National Health and Nutrition Examination Survey (NHANES).MethodsThe study population was derived from five NHANES cycles: 2003–2006, 2009–2014, and survival follow‐up was as of December 31, 2019. The association between SII and psoriasis and its comorbidities was analyzed using weighted multivariate logistic regression models. Weighted COX regression was used to calculate hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs). Restricted cubic spline, subgroup and sensitivity analyses were also used. Logarithmic conversion was performed on SII(log2SII) to reduce the impact of outliers.ResultsA total of 21,431 participants were included in this study. As a continuous variable, log2SII was significantly associated with psoriasis in the fully adjusted model [OR = 1.20(1.04–1.39), p = .01]. log2SII remained positively associated with psoriasis after excluding participants with a history of cancer or cardiovascular disease (CVD), or non‐Hispanic black participants. Among psoriasis patients, log2SII was significantly associated with metabolic syndrome (MetS) [OR = 1.68(1.19,2.38), p = .004] and all‐cause mortality [HR = 1.48(1.09,1.99), p = .01]. Similar results were consistently observed when SII was analyzed as a categorical variable (in quartiles).ConclusionThis study suggested a positive association between SII and the prevalence of psoriasis. Among psoriasis patients, SII was positively correlated with MetS and all‐cause mortality.

show abstract

Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis

Cited by 26 publications

References 33 publications

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

Predictive value of SII and sd-LDL for contrast-induced acute kidney injury in STEMI patients undergoing percutaneous coronary intervention

Association Between Systemic Immune‐Inflammation Index and Psoriasis, Psoriasis Comorbidities, and All‐Cause Mortality: A Study Based on NHANES

Contact Info

Product

Resources

About